Rapid Diagnosis of Myocardial Infarction Within 6 Hours

Randox have developed a multi marker Cardiac biochip array for rapid diagnosis of myocardial infarction (MI) and identification of at risk acute coronary syndrome (ACS) patients. This array simultaneously and quantitatively tests four cardiac biomarkers using a single patient sample, reliable within the critical 3-6 hour post pain onset treatment window.

The Randox Cardiac Array combines the gold standard Troponin test with CK-MB, Myoglobin and heart Fatty Acid Binding Protein (h-FABP). h-FABP is gaining a reputation as an ischaemic indicator and as an early marker of cardiac muscle damage. As a single marker, h-FABP has been shown to be a powerful identifier of high risk MI patients, independent of Troponin. As a multi-analyte test, the Cardiac Biochip Array provides even greater diagnostic performance, with 20% increased sensitivity compared to testing Troponin alone and a 98% rule out for MI within 3-6 hours of pain onset. This means that cardiac patients requiring intervention are given immediate priority and that non-MI patients can be quickly and effectively managed, freeing up hospital resources.

The innovative Randox biochip array technology is based on familiar ELISA principles, with the Cardiac Array utilising sandwich chemiluminescent immunoassays. Three biochip analysers are available; the fully automated, high throughput Evidence, the semi automated medium volume Investigator and the new, fully automated Multistat. Using advanced technology, the Multistat is an easy to use, near-patient biochip platform providing rapid laboratory-quality results in 20 minutes. All Randox biochip analysers are suitable for a comprehensive range of biochip arrays, providing a cost effective, multi-analyte solution to your clinical and research needs.

To complement the clinical Cardiac array, Randox also offer an expanded research array - Cardiac Plus. In addition to the four markers on the Cardiac biochip, Cardiac Plus contains Glycogen Phosphorylase BB and Carbonic Anhydrase III. This combination has already found utility in sports medicine, for example, where elite athletes can monitor cardiac stress during and post-endurance competitions.